

Ref: GLL/BSE/2025-26/June -

To
The General Manager,
Corporate Relations Department,
BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, **Mumbai - 400001**. Maharashtra State, India.

Script Code: 531739

To

The Calcutta Stock Exchange Limited,

#7, Lyons Range, Murgighata, Dalhousie, **Kolkata - 700001**, West Bengal State, India.

Scrip Code: 26178

Dear Sir/Madam,

То

The Listing Manager,

The Ahmedabad Stock Exchange Limited A-2, Kamdhenu Complex, Opp. Sahajanand College, 120 Feet Ring Road, Panjara Pol, Ambawadi, **Ahmedabad - 380015**. Gujarat State, India.

Date: June 04, 2025

Script Code:

Sub: Outcome of the Board Meeting of Gennex Laboratories Limited held on June 04, 2025 - Scrip Code: 531739/GENNEX

Reg: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') – Conversion of Warrants into Equity Shares.

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that Board of Directors of the Company, at its meeting held today, on June 04, 2025 has considered and approved the following:

1. Allotment of 40,00,000 Equity Shares upon Conversion of Warrants to the member of promoter group on Preferential basis

The requisite disclosures are set out in Annexure A to this letter.

We hereby submit that the Board Meeting had commenced at 02:00 PM and concluded at 02:30 PM.

This intimation is also uploaded on the Company website: www.gennexlab.com

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

#### For Gennex Laboratories Limited

### Dinesh Kumar Kejriwal

Company Secretary & Compliance Officer

## **Gennex Laboratories Limited**



### Annexure A

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI SEBI Circular No.'s SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 and CIR/CFD/ CMD/4/2015 dated September 9, 2015 and Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr.	Disclosure Item	Details		
No.				
i.	Type of Securities issued	Equity Shares on Conversion of Warrants		
ii.	Type of issuance	Preferential Allotment		
iii.	Total number of securities issued or the total amount for which the securities issued (approximately)	Allotment of 40,00,000 (Forty Lakhs) Equity Shares of face value of INR. 1/- each upon conversion of 40,00,000 (Forty Lakhs) Warrants at an issue price of INR. 14.75/- (Indian Rupees Fourteen and Seventy-Five Paisa Only) each upon receipt of "Warrant Exercise Amount".		

# Additional Information in case of Preferential Issue (Disclosure post allotment of Securities)

Sr. No.	Disclosure Item	Details					
i.	Name of the investor(s)	PREMIER FISCAL SERVICES PVT. LTD.					
ii.	Post allotment of securities –Outcome of the subscription, Issue price / allotted price (in case of convertibles), Number of investors	i. Outcome of the subscription:  Details of the shareholding of the allottees in the Company, prior to and after the said allotment, is as under:					
		Particul ars (Name of the Investor s)	Pre-Preferential Allotment		No. of Equity Shares	Post Preferential Allotment	
			No. of Equity Shares	%	allotted	No. of Equity Shares	%
		PREM IER FISC AL SERV ICES PVT. LTD. ii. Issue Pr	3,75,3 8,000	16.50 14.75 per s	40,00, 000	4,15,3 8,000	17.95
		iii. Number of Investors: (1) One					

## **Gennex Laboratories Limited**



iii.	In case of convertibles intimation on conversion of securities or on lapse of the tenure of the instrument;	Equity shares are being allotted upon Conversion of Warrants.

### For Gennex Laboratories Limited

### Dinesh Kumar Kejriwal

Company Secretary & Compliance Officer